
Sign up to save your podcasts
Or


Tim Boreham, Stockhead's small caps correspondent joins The Australian's Wealth Editor James Kirby on this week's show. They discuss how Biotech gets hit hardest of all, one reason this sector may recover first and three ASX biotech stocks for you to consider.
See omnystudio.com/listener for privacy information.
By The Australian4.5
1010 ratings
Tim Boreham, Stockhead's small caps correspondent joins The Australian's Wealth Editor James Kirby on this week's show. They discuss how Biotech gets hit hardest of all, one reason this sector may recover first and three ASX biotech stocks for you to consider.
See omnystudio.com/listener for privacy information.

14 Listeners

66 Listeners

223 Listeners

84 Listeners

18 Listeners

137 Listeners

53 Listeners

7,060 Listeners

15 Listeners

63 Listeners

19 Listeners

1,820 Listeners

26 Listeners

334 Listeners

293 Listeners

9 Listeners

37 Listeners

2 Listeners

32 Listeners

242 Listeners

113 Listeners

55 Listeners

238 Listeners

294 Listeners

6 Listeners

23 Listeners

23 Listeners

10 Listeners

354 Listeners

6 Listeners

10 Listeners

422 Listeners